2025-03-19 12:31Financial Performance & Cash Position - HUTCHMED achieved profitability ahead of schedule, driven by strong performance of FRUZAQLA®[100] - The company's cash, cash equivalents, and short-term investments amounted to $836 million as of December 31, 2024[14] - Oncology revenue reached $3634 million in 2024, including $271 million from oncology products revenue and $71 million from royalties[18] - The company projects oncology revenue guidance of $350-$450 million for 2025[18] Commercial Success & Growth - Global in-market sales of oncology products reached $501 million in 2024, a 134% increase compared to $2136 million in 2023[20] - FRUZAQLA® in-market sales were $2906 million in 2024, a significant increase from $151 million in 2023, representing a growth of +1,825%[20] - ELUNATE® in-market sales reached $115 million in 2024, a 7% increase from $1075 million in 2023[20] - SULANDA® in-market sales were $49 million in 2024, a 12% increase from $439 million in 2023[20] Pipeline Development & Regulatory Milestones - The company has 13+ potential NDAs & sNDAs in the next 3 years[45] - Fruquintinib received conditional approval in China for endometrial cancer in December 2024[49] - A Phase III study of Fruquintinib (FRUSICA-2) in 2L RCC showed positive topline results, with China NDA filing expected[47]